Pirfenidone Tablet Suppliers & Bulk Manufacturers
Available Forms: Tablet
Available Strengths: 267 mg , 801 mg
Reference Brands: Esbriet(US & EU)
Category:
Respiratory Disorder
Pirfenidone is an oral antifibrotic medication used to treat idiopathic pulmonary fibrosis (IPF). It slows lung scarring, improves lung function, and reduces inflammation. Marketed as Esbriet in the US and EU, it’s taken three times daily. Common side effects include nausea, rash, and liver enzyme changes.
Pirfenidone Tablet is available in Tablet
and strengths such as 267 mg , 801 mg.
Sourced from GMP-certified and ISO-compliant manufacturers, this API meets
global pharmacopeia standards (USP/EP/JP as applicable). Ideal for pharmaceutical
formulation and commercial manufacturing, Pirfenidone Tablet is supplied in
bulk quantities with complete regulatory support including DMF, COA, and MSDS.
|
Technical Specifications & Supply Details
|
| Lead Time |
7 to 60 days (depending on batch size & schedule) |
| MOQ |
As per manufacturer’s batch size |
| COA |
Available with every batch |
| Regulatory Dossier / DMF |
Available upon request |
| Export Documentation |
FSC, COA, Manufacturing License, Product Permission |
| Standards |
IP, BP, USP |
| Certifications |
WHO-GMP, EU-GMP, USFDA (as applicable) |
Pirfenidone Tablet can be exported to over 30 countries across Asia, Africa, Europe,
and Latin America. Flexible packaging, competitive pricing, and a verified supplier
network make Pharmatradz a trusted sourcing partner for pharmaceutical companies
and contract manufacturers worldwide.
Product Description:
Pirfenidone is an FDA- and EMA-approved oral antifibrotic drug used to treat idiopathic pulmonary fibrosis (IPF)—a chronic lung disease marked by progressive scarring of lung tissue. Marketed under the brand name Esbriet, pirfenidone helps slow lung function decline, reduce inflammation, and limit fibrosis by inhibiting pro-fibrotic cytokines like TGF-β. Available in 267 mg and 801 mg tablet strengths, it is usually taken three times daily with food. Pirfenidone improves quality of life and delays disease progression in IPF patients. Common side effects include nausea, rash, and photosensitivity. Regular liver monitoring is advised during treatment.
Disclaimer: By continuing to browse, you agree to the terms of use of this website and the Trade Marks displayed, in compliance with the provisions of the Trademark Act, 1999, Section 30 and 30(1) under 'Fair use.'
The Trade Mark owner has been correctly identified under the heading Manufacturer / TM Owner as required by the Act.
Back to Listing